8 results on '"Torres Acosta, Alejandro"'
Number of results to display per page
Search Results
2. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
- Author
-
Reijers, Irene L. M., Menzies, Alexander M., van Akkooi, Alexander C. J., Versluis, Judith M., van den Heuvel, Noëlle M. J., Saw, Robyn P. M., Pennington, Thomas E., Kapiteijn, Ellen, van der Veldt, Astrid A. M., Suijkerbuijk, Karijn P. M., Hospers, Geke A. P., Rozeman, Elisa A., Klop, Willem M. C., van Houdt, Winan J., Sikorska, Karolina, van der Hage, Jos A., Grünhagen, Dirk J., Wouters, Michel W., Witkamp, Arjen J., Zuur, Charlotte L., Lijnsvelt, Judith M., Torres Acosta, Alejandro, Grijpink-Ongering, Lindsay G., Gonzalez, Maria, Jóźwiak, Katarzyna, Bierman, Carolien, Shannon, Kerwin F., Ch’ng, Sydney, Colebatch, Andrew J., Spillane, Andrew J., Haanen, John B. A. G., Rawson, Robert V., van de Wiel, Bart A., van de Poll-Franse, Lonneke V., Scolyer, Richard A., Boekhout, Annelies H., Long, Georgina V., and Blank, Christian U.
- Published
- 2022
- Full Text
- View/download PDF
3. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
- Author
-
Rohaan, Maartje W., primary, Borch, Troels H., additional, van den Berg, Joost H., additional, Met, Özcan, additional, Kessels, Rob, additional, Geukes Foppen, Marnix H., additional, Stoltenborg Granhøj, Joachim, additional, Nuijen, Bastiaan, additional, Nijenhuis, Cynthia, additional, Jedema, Inge, additional, van Zon, Maaike, additional, Scheij, Saskia, additional, Beijnen, Jos H., additional, Hansen, Marten, additional, Voermans, Carlijn, additional, Noringriis, Inge M., additional, Monberg, Tine J., additional, Holmstroem, Rikke B., additional, Wever, Lidwina D.V., additional, van Dijk, Marloes, additional, Grijpink-Ongering, Lindsay G., additional, Valkenet, Ludy H.M., additional, Torres Acosta, Alejandro, additional, Karger, Matthias, additional, Borgers, Jessica S.W., additional, ten Ham, Renske M.T., additional, Retèl, Valesca P., additional, van Harten, Wim H., additional, Lalezari, Ferry, additional, van Tinteren, Harm, additional, van der Veldt, Astrid A.M., additional, Hospers, Geke A.P., additional, Stevense-den Boer, Marion A.M., additional, Suijkerbuijk, Karijn P.M., additional, Aarts, Maureen J.B., additional, Piersma, Djura, additional, van den Eertwegh, Alfons J.M., additional, de Groot, Jan-Willem B., additional, Vreugdenhil, Gerard, additional, Kapiteijn, Ellen, additional, Boers-Sonderen, Marye J., additional, Fiets, W. Edward, additional, van den Berkmortel, Franchette W.P.J., additional, Ellebaek, Eva, additional, Hölmich, Lisbet R., additional, van Akkooi, Alexander C.J., additional, van Houdt, Winan J., additional, Wouters, Michel W.J.M., additional, van Thienen, Johannes V., additional, Blank, Christian U., additional, Meerveld-Eggink, Aafke, additional, Klobuch, Sebastian, additional, Wilgenhof, Sofie, additional, Schumacher, Ton N., additional, Donia, Marco, additional, Svane, Inge Marie, additional, and Haanen, John B.A.G., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
- Author
-
Rohaan, Maartje W, Borch, Troels H, van den Berg, Joost H, Met, Özcan, Kessels, Rob, Geukes Foppen, Marnix H, Stoltenborg Granhøj, Joachim, Nuijen, Bastiaan, Nijenhuis, Cynthia, Jedema, Inge, van Zon, Maaike, Scheij, Saskia, Beijnen, Jos H, Hansen, Marten, Voermans, Carlijn, Noringriis, Inge M, Monberg, Tine J, Holmstroem, Rikke B, Wever, Lidwina D V, van Dijk, Marloes, Grijpink-Ongering, Lindsay G, Valkenet, Ludy H M, Torres Acosta, Alejandro, Karger, Matthias, Borgers, Jessica S W, Ten Ham, Renske M T, Retèl, Valesca P, van Harten, Wim H, Lalezari, Ferry, van Tinteren, Harm, van der Veldt, Astrid A M, Hospers, Geke A P, Stevense-den Boer, Marion A M, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, Piersma, Djura, van den Eertwegh, Alfons J M, de Groot, Jan-Willem B, Vreugdenhil, Gerard, Kapiteijn, Ellen, Boers-Sonderen, Marye J, Fiets, W Edward, van den Berkmortel, Franchette W P J, Ellebaek, Eva, Hölmich, Lisbet R, van Akkooi, Alexander C J, van Houdt, Winan J, Wouters, Michel W J M, van Thienen, Johannes V, Blank, Christian U, Meerveld-Eggink, Aafke, Klobuch, Sebastian, Wilgenhof, Sofie, Schumacher, Ton N, Donia, Marco, Svane, Inge Marie, Haanen, John B A G, Rohaan, Maartje W, Borch, Troels H, van den Berg, Joost H, Met, Özcan, Kessels, Rob, Geukes Foppen, Marnix H, Stoltenborg Granhøj, Joachim, Nuijen, Bastiaan, Nijenhuis, Cynthia, Jedema, Inge, van Zon, Maaike, Scheij, Saskia, Beijnen, Jos H, Hansen, Marten, Voermans, Carlijn, Noringriis, Inge M, Monberg, Tine J, Holmstroem, Rikke B, Wever, Lidwina D V, van Dijk, Marloes, Grijpink-Ongering, Lindsay G, Valkenet, Ludy H M, Torres Acosta, Alejandro, Karger, Matthias, Borgers, Jessica S W, Ten Ham, Renske M T, Retèl, Valesca P, van Harten, Wim H, Lalezari, Ferry, van Tinteren, Harm, van der Veldt, Astrid A M, Hospers, Geke A P, Stevense-den Boer, Marion A M, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, Piersma, Djura, van den Eertwegh, Alfons J M, de Groot, Jan-Willem B, Vreugdenhil, Gerard, Kapiteijn, Ellen, Boers-Sonderen, Marye J, Fiets, W Edward, van den Berkmortel, Franchette W P J, Ellebaek, Eva, Hölmich, Lisbet R, van Akkooi, Alexander C J, van Houdt, Winan J, Wouters, Michel W J M, van Thienen, Johannes V, Blank, Christian U, Meerveld-Eggink, Aafke, Klobuch, Sebastian, Wilgenhof, Sofie, Schumacher, Ton N, Donia, Marco, Svane, Inge Marie, and Haanen, John B A G
- Abstract
Background Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) have shown promising responses, but data from phase 3 trials are lacking to determine the role of TILs in treating advanced melanoma. Methods In this phase 3, multicenter, open-label trial, we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy (ipilimumab at 3 mg per kilogram of body weight). Infusion of at least 5×109 TILs was preceded by nonmyeloablative, lymphodepleting chemotherapy (cyclophosphamide plus fludarabine) and followed by high-dose interleukin-2. The primary end point was progression-free survival. Results A total of 168 patients (86% with disease refractory to anti-programmed death 1 treatment) were assigned to receive TILs (84 patients) or ipilimumab (84 patients). In the intention-to-treat population, median progression-free survival was 7.2 months (95% confidence interval [CI], 4.2 to 13.1) in the TIL group and 3.1 months (95% CI, 3.0 to 4.3) in the ipilimumab group (hazard ratio for progression or death, 0.50; 95% CI, 0.35 to 0.72; P<0.001); 49% (95% CI, 38 to 60) and 21% (95% CI, 13 to 32) of the patients, respectively, had an objective response. Median overall survival was 25.8 months (95% CI, 18.2 to not reached) in the TIL group and 18.9 months (95% CI, 13.8 to 32.6) in the ipilimumab group. Treatment-related adverse events of grade 3 or higher occurred in all patients who received TILs and in 57% of those who received ipilimumab; in the TIL group, these events were mainly chemotherapy-related myelosuppression. Conclusions In patients with advanced melanoma, progression-free survival was significantly longer among those who received TIL therapy than amon
- Published
- 2022
5. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
- Author
-
Rohaan, Maartje W., Borch, Troels H., Van Den Berg, Joost H., Met, Özcan, Kessels, Rob, Geukes Foppen, Marnix H., Stoltenborg Granhøj, Joachim, Nuijen, Bastiaan, Nijenhuis, Cynthia, Jedema, Inge, Van Zon, Maaike, Scheij, Saskia, Beijnen, Jos H., Hansen, Marten, Voermans, Carlijn, Noringriis, Inge M., Monberg, Tine J., Holmstroem, Rikke B., Wever, Lidwina D.V., Van Dijk, Marloes, Grijpink-Ongering, Lindsay G., Valkenet, Ludy H.M., Torres Acosta, Alejandro, Karger, Matthias, Borgers, Jessica S.W., Ten Ham, Renske M.T., Retèl, Valesca P., Van Harten, Wim H., Lalezari, Ferry, Van Tinteren, Harm, Van Der Veldt, Astrid A.M., Hospers, Geke A.P., Stevense-Den Boer, Marion A.M., Suijkerbuijk, Karijn P.M., Aarts, Maureen J.B., Piersma, Djura, Van Den Eertwegh, Alfons J.M., De Groot, Jan Willem B., Vreugdenhil, Gerard, Kapiteijn, Ellen, Boers-Sonderen, Marye J., Fiets, W. Edward, Van Den Berkmortel, Franchette W.P.J., Ellebaek, Eva, Hölmich, Lisbet R., Van Akkooi, Alexander C.J., Van Houdt, Winan J., Wouters, Michel W.J.M., Van Thienen, Johannes V., Blank, Christian U., Meerveld-Eggink, Aafke, Klobuch, Sebastian, Wilgenhof, Sofie, Schumacher, Ton N., Donia, Marco, Svane, Inge Marie, Haanen, John B.A.G., Rohaan, Maartje W., Borch, Troels H., Van Den Berg, Joost H., Met, Özcan, Kessels, Rob, Geukes Foppen, Marnix H., Stoltenborg Granhøj, Joachim, Nuijen, Bastiaan, Nijenhuis, Cynthia, Jedema, Inge, Van Zon, Maaike, Scheij, Saskia, Beijnen, Jos H., Hansen, Marten, Voermans, Carlijn, Noringriis, Inge M., Monberg, Tine J., Holmstroem, Rikke B., Wever, Lidwina D.V., Van Dijk, Marloes, Grijpink-Ongering, Lindsay G., Valkenet, Ludy H.M., Torres Acosta, Alejandro, Karger, Matthias, Borgers, Jessica S.W., Ten Ham, Renske M.T., Retèl, Valesca P., Van Harten, Wim H., Lalezari, Ferry, Van Tinteren, Harm, Van Der Veldt, Astrid A.M., Hospers, Geke A.P., Stevense-Den Boer, Marion A.M., Suijkerbuijk, Karijn P.M., Aarts, Maureen J.B., Piersma, Djura, Van Den Eertwegh, Alfons J.M., De Groot, Jan Willem B., Vreugdenhil, Gerard, Kapiteijn, Ellen, Boers-Sonderen, Marye J., Fiets, W. Edward, Van Den Berkmortel, Franchette W.P.J., Ellebaek, Eva, Hölmich, Lisbet R., Van Akkooi, Alexander C.J., Van Houdt, Winan J., Wouters, Michel W.J.M., Van Thienen, Johannes V., Blank, Christian U., Meerveld-Eggink, Aafke, Klobuch, Sebastian, Wilgenhof, Sofie, Schumacher, Ton N., Donia, Marco, Svane, Inge Marie, and Haanen, John B.A.G.
- Abstract
Background Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) have shown promising responses, but data from phase 3 trials are lacking to determine the role of TILs in treating advanced melanoma. Methods In this phase 3, multicenter, open-label trial, we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy (ipilimumab at 3 mg per kilogram of body weight). Infusion of at least 5×109 TILs was preceded by nonmyeloablative, lymphodepleting chemotherapy (cyclophosphamide plus fludarabine) and followed by high-dose interleukin-2. The primary end point was progression-free survival. Results A total of 168 patients (86% with disease refractory to anti-programmed death 1 treatment) were assigned to receive TILs (84 patients) or ipilimumab (84 patients). In the intention-to-treat population, median progression-free survival was 7.2 months (95% confidence interval [CI], 4.2 to 13.1) in the TIL group and 3.1 months (95% CI, 3.0 to 4.3) in the ipilimumab group (hazard ratio for progression or death, 0.50; 95% CI, 0.35 to 0.72; P<0.001); 49% (95% CI, 38 to 60) and 21% (95% CI, 13 to 32) of the patients, respectively, had an objective response. Median overall survival was 25.8 months (95% CI, 18.2 to not reached) in the TIL group and 18.9 months (95% CI, 13.8 to 32.6) in the ipilimumab group. Treatment-related adverse events of grade 3 or higher occurred in all patients who received TILs and in 57% of those who received ipilimumab; in the TIL group, these events were mainly chemotherapy-related myelosuppression. Conclusions In patients with advanced melanoma, progression-free survival was significantly longer among those who received TIL therapy than amon
- Published
- 2022
6. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
- Author
-
HEE, MS Medische Oncologie, Cancer, Infection & Immunity, Rohaan, Maartje W, Borch, Troels H, van den Berg, Joost H, Met, Özcan, Kessels, Rob, Geukes Foppen, Marnix H, Stoltenborg Granhøj, Joachim, Nuijen, Bastiaan, Nijenhuis, Cynthia, Jedema, Inge, van Zon, Maaike, Scheij, Saskia, Beijnen, Jos H, Hansen, Marten, Voermans, Carlijn, Noringriis, Inge M, Monberg, Tine J, Holmstroem, Rikke B, Wever, Lidwina D V, van Dijk, Marloes, Grijpink-Ongering, Lindsay G, Valkenet, Ludy H M, Torres Acosta, Alejandro, Karger, Matthias, Borgers, Jessica S W, Ten Ham, Renske M T, Retèl, Valesca P, van Harten, Wim H, Lalezari, Ferry, van Tinteren, Harm, van der Veldt, Astrid A M, Hospers, Geke A P, Stevense-den Boer, Marion A M, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, Piersma, Djura, van den Eertwegh, Alfons J M, de Groot, Jan-Willem B, Vreugdenhil, Gerard, Kapiteijn, Ellen, Boers-Sonderen, Marye J, Fiets, W Edward, van den Berkmortel, Franchette W P J, Ellebaek, Eva, Hölmich, Lisbet R, van Akkooi, Alexander C J, van Houdt, Winan J, Wouters, Michel W J M, van Thienen, Johannes V, Blank, Christian U, Meerveld-Eggink, Aafke, Klobuch, Sebastian, Wilgenhof, Sofie, Schumacher, Ton N, Donia, Marco, Svane, Inge Marie, Haanen, John B A G, HEE, MS Medische Oncologie, Cancer, Infection & Immunity, Rohaan, Maartje W, Borch, Troels H, van den Berg, Joost H, Met, Özcan, Kessels, Rob, Geukes Foppen, Marnix H, Stoltenborg Granhøj, Joachim, Nuijen, Bastiaan, Nijenhuis, Cynthia, Jedema, Inge, van Zon, Maaike, Scheij, Saskia, Beijnen, Jos H, Hansen, Marten, Voermans, Carlijn, Noringriis, Inge M, Monberg, Tine J, Holmstroem, Rikke B, Wever, Lidwina D V, van Dijk, Marloes, Grijpink-Ongering, Lindsay G, Valkenet, Ludy H M, Torres Acosta, Alejandro, Karger, Matthias, Borgers, Jessica S W, Ten Ham, Renske M T, Retèl, Valesca P, van Harten, Wim H, Lalezari, Ferry, van Tinteren, Harm, van der Veldt, Astrid A M, Hospers, Geke A P, Stevense-den Boer, Marion A M, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, Piersma, Djura, van den Eertwegh, Alfons J M, de Groot, Jan-Willem B, Vreugdenhil, Gerard, Kapiteijn, Ellen, Boers-Sonderen, Marye J, Fiets, W Edward, van den Berkmortel, Franchette W P J, Ellebaek, Eva, Hölmich, Lisbet R, van Akkooi, Alexander C J, van Houdt, Winan J, Wouters, Michel W J M, van Thienen, Johannes V, Blank, Christian U, Meerveld-Eggink, Aafke, Klobuch, Sebastian, Wilgenhof, Sofie, Schumacher, Ton N, Donia, Marco, Svane, Inge Marie, and Haanen, John B A G
- Published
- 2022
7. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
- Author
-
MS Medische Oncologie, Infection & Immunity, Cancer, MS CGO, Reijers, Irene L M, Menzies, Alexander M, van Akkooi, Alexander C J, Versluis, Judith M, van den Heuvel, Noëlle M J, Saw, Robyn P M, Pennington, Thomas E, Kapiteijn, Ellen, van der Veldt, Astrid A M, Suijkerbuijk, Karijn P M, Hospers, Geke A P, Rozeman, Elisa A, Klop, Willem M C, van Houdt, Winan J, Sikorska, Karolina, van der Hage, Jos A, Grünhagen, Dirk J, Wouters, Michel W, Witkamp, Arjen J, Zuur, Charlotte L, Lijnsvelt, Judith M, Torres Acosta, Alejandro, Grijpink-Ongering, Lindsay G, Gonzalez, Maria, Jóźwiak, Katarzyna, Bierman, Carolien, Shannon, Kerwin F, Ch'ng, Sydney, Colebatch, Andrew J, Spillane, Andrew J, Haanen, John B A G, Rawson, Robert V, van de Wiel, Bart A, van de Poll-Franse, Lonneke V, Scolyer, Richard A, Boekhout, Annelies H, Long, Georgina V, Blank, Christian U, MS Medische Oncologie, Infection & Immunity, Cancer, MS CGO, Reijers, Irene L M, Menzies, Alexander M, van Akkooi, Alexander C J, Versluis, Judith M, van den Heuvel, Noëlle M J, Saw, Robyn P M, Pennington, Thomas E, Kapiteijn, Ellen, van der Veldt, Astrid A M, Suijkerbuijk, Karijn P M, Hospers, Geke A P, Rozeman, Elisa A, Klop, Willem M C, van Houdt, Winan J, Sikorska, Karolina, van der Hage, Jos A, Grünhagen, Dirk J, Wouters, Michel W, Witkamp, Arjen J, Zuur, Charlotte L, Lijnsvelt, Judith M, Torres Acosta, Alejandro, Grijpink-Ongering, Lindsay G, Gonzalez, Maria, Jóźwiak, Katarzyna, Bierman, Carolien, Shannon, Kerwin F, Ch'ng, Sydney, Colebatch, Andrew J, Spillane, Andrew J, Haanen, John B A G, Rawson, Robert V, van de Wiel, Bart A, van de Poll-Franse, Lonneke V, Scolyer, Richard A, Boekhout, Annelies H, Long, Georgina V, and Blank, Christian U
- Published
- 2022
8. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
- Author
-
Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, Hoeijmakers LL, Saw RPM, Lijnsvelt JM, Maher NG, Pulleman SM, Gonzalez M, Torres Acosta A, van Houdt WJ, Lo SN, Kuijpers AMJ, Spillane A, Klop WMC, Pennington TE, Zuur CL, Shannon KF, Seinstra BA, Rawson RV, Haanen JBAG, Ch'ng S, Naipal KAT, Stretch J, van Thienen JV, Rtshiladze MA, Wilgenhof S, Kapoor R, Meerveld-Eggink A, Grijpink-Ongering LG, van Akkooi ACJ, Reijers ILM, Gyorki DE, Grünhagen DJ, Speetjens FM, Vliek SB, Placzke J, Spain L, Stassen RC, Amini-Adle M, Lebbé C, Faries MB, Robert C, Ascierto PA, van Rijn R, van den Berkmortel FWPJ, Piersma D, van der Westhuizen A, Vreugdenhil G, Aarts MJB, Stevense-den Boer MAM, Atkinson V, Khattak M, Andrews MC, van den Eertwegh AJM, Boers-Sonderen MJ, Hospers GAP, Carlino MS, de Groot JB, Kapiteijn E, Suijkerbuijk KPM, Rutkowski P, Sandhu S, van der Veldt AAM, and Long GV
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Chemotherapy, Adjuvant methods, Chemotherapy, Adjuvant statistics & numerical data, Disease-Free Survival, Kaplan-Meier Estimate, Progression-Free Survival, Young Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Ipilimumab administration & dosage, Ipilimumab adverse effects, Ipilimumab therapeutic use, Melanoma mortality, Melanoma pathology, Melanoma therapy, Neoadjuvant Therapy methods, Neoadjuvant Therapy statistics & numerical data, Neoplasm Staging, Nivolumab therapeutic use, Nivolumab adverse effects, Nivolumab administration & dosage, Skin Neoplasms mortality, Skin Neoplasms pathology, Skin Neoplasms therapy
- Abstract
Background: In phase 1-2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy., Methods: In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma to two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery or surgery followed by 12 cycles of adjuvant nivolumab. Only patients in the neoadjuvant group with a partial response or nonresponse received adjuvant treatment. The primary end point was event-free survival., Results: A total of 423 patients underwent randomization. At a median follow-up of 9.9 months, the estimated 12-month event-free survival was 83.7% (99.9% confidence interval [CI], 73.8 to 94.8) in the neoadjuvant group and 57.2% (99.9% CI, 45.1 to 72.7) in the adjuvant group. The difference in restricted mean survival time was 8.00 months (99.9% CI, 4.94 to 11.05; P<0.001; hazard ratio for progression, recurrence, or death, 0.32; 99.9% CI, 0.15 to 0.66). In the neoadjuvant group, 59.0% of patients had a major pathological response, 8.0% had a partial response, 26.4% had a nonresponse (>50% residual viable tumor), and 2.4% had progression; in 4.2%, surgery had not yet been performed or was omitted. The estimated 12-month recurrence-free survival was 95.1% in patients in the neoadjuvant group who had a major pathological response, 76.1% among those with a partial response, and 57.0% among those with a nonresponse. Adverse events of grade 3 or higher that were related to systemic treatment occurred in 29.7% of patients in the neoadjuvant group and in 14.7% in the adjuvant group., Conclusions: Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free survival than surgery followed by adjuvant nivolumab. (Funded by Bristol Myers Squibb and others; NADINA ClinicalTrials.gov number, NCT04949113.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.